Print
EmailGeneric Name: oxcarbazepine
FDA Alerts-
Special Alerts:
[Posted 01/31/2008] FDA informed healthcare professionals that the Agency has analyzed reports of suicidality (suicidal behavior or ideation) from placebo-controlled clinical studies of eleven drugs used to treat epilepsy as well as psychiatric disorders, and other conditions. In the FDA's analysis, patients receiving antiepileptic drugs had approximately twice the risk of suicidal behavior or ideation (0.43%) compared to patients receiving placebo (0.22%). The increased risk of suicidal behavior and suicidal ideation was observed as early as one week after starting the antiepileptic drug and continued through 24 weeks. The results were generally consistent among the eleven drugs. The relative risk for suicidality was higher in patients with epilepsy compared to patients who were given one of the drugs in the class for psychiatric or other conditions.
Healthcare professionals should closely monitor all patients currently taking or starting any antiepileptic drug for notable changes in behavior that could indicate the emergence or worsening of suicidal thoughts or behavior or depression.
The drugs included in the analyses include (some of these drugs are also available in generic form):
- Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, Tegretol XR)
- Felbamate (marketed as Felbatol)
- Gabapentin (marketed as Neurontin)
- Lamotrigine (marketed as Lamictal)
- Levetiracetam (marketed as Keppra)
- Oxcarbazepine (marketed as Trileptal)
- Pregabalin (marketed as Lyrica)
- Tiagabine (marketed as Gabitril)
- Topiramate (marketed as Topamax)
- Valproate (marketed as Depakote, Depakote ER, Depakene, Depacon)
- Zonisamide (marketed as Zonegran)
Although the 11 drugs listed above were the ones included in the analysis, FDA expects that the increased risk of suicidality is shared by all antiepileptic drugs and anticipates that the class labeling changes will be applied broadly. For more information visit the FDA website at: http://www.fda.gov/medwatch/safety/2008/safety08.htm#Antiepileptic and http://www.fda.gov/cder/drug/InfoSheets/HCP/antiepilepticsHCP.htm.
Media Gallery-
- images
- Drug Info Tools
-
Healthline Part D Plan Selector
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
- Basic Info
- Top Questions
- Clinical Info
- Interactions
Before using oxcarbazepine, tell your doctor about all other seizure medications you are taking, including:
-
carbamazepine (Carbatrol, Tegretol);
-
phenobarbital (Luminal, Solfoton);
-
phenytoin (Dilantin); or
-
valproic acid (Depakene).
Get emergency medical help if you have any of these
Oxcarbazepine can reduce the sodium in your body to dangerously low levels, which can cause a life-threatening electrolyte imbalance. Contact your doctor right away if you have nausea, vomiting, weakness, thirst, loss of appetite, headache, confusion, hallucinations, muscle pain or weakness, and/or increased or more severe seizures.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, depression, anxiety, or if you feel agitated, hostile, restless, hyperactive (mentally or physically), or have thoughts about suicide or hurting yourself.
Call your doctor at once if you have any of these serious side effects:
-
sore throat, and headache with a severe blistering, peeling, and red skin rash;
-
jaundice (yellowing of the skin or eyes);
-
fever, swollen glands, flu-like symptoms;
-
easy bruising or bleeding, unusual weakness;
-
urinating less than usual or not at all; or
-
increased seizures.
Less serious side effects may include:
-
mild nausea, vomiting, stomach pain, diarrhea;
-
problems with speech, balance, or coordination;
-
blurred vision;
-
mental slowness, trouble concentrating;
-
tremors or shaking;
-
dizziness, drowsiness; or
-
skin rash.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect.